Ocrelizumab (ocrevus)

Ocrelizumab Simply known as ocrevus is a disease modifying drug (DMD) that is approved for relapsing remitting and for primary progressive MS. it is given to in as an  intravenous infusion every six months. The first dose is given as two separate infusions, two weeks apart. Further doses are given as one infusion every six months. . The infusions take around 3 to 4 hours to complete.

Side Effects

Common side effect may include

  • infusion-related reactions
  • flu (influenza)
  • sinus infections
  • bronchitis (bronchial tube inflammation)
  • herpes infection (cold sore or shingles)
  • infection of the stomach and bowel (gastroenteritis)
  • viral infections
  • skin infection (cellulitis)

A full list of side effects is included in the manufacturer’s Patient Information Leaflet

What Ocrevus Patients Say